RxDoctor Payments Data

Kavina Naik

Physician Assistant · New York, NYNPI 1972277812

Payments from drug & device makers

$986in general payments, 2019–2025

Across 24 payments — averaging $41.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$276
  • AstraZeneca$230
  • Tactile Systems Technology Inc$166
  • Lexicon Pharmaceuticals, Inc.$114
  • Bard Peripheral Vascular, Inc.$50
  • Boehringer Ingelheim$41
  • plus $109 from 6 others

What the payments were for

  • Food & beverage$986100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$986 in reported general payments places this provider in the 75th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$9,944
Medicare patients
71
Services billed
101

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban51$48,946
EntrestoSacubitril/Valsartan29$39,400
XareltoRivaroxaban34$29,694
FarxigaDapagliflozin Propanediol25$20,479
Metoprolol Succinate126$1,568
Atorvastatin Calcium82$1,159
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide31$692
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide20$391
Isosorbide Mononitrate ErIsosorbide Mononitrate48$356
Amlodipine Besylate82$289
Losartan Potassium39$270
ClopidogrelClopidogrel Bisulfate30$219
Carvedilol38$142
Lisinopril24$109
Hydrochlorothiazide37$90

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$14$48,94651 claims
NovartisEntresto$13$39,40029 claims
Johnson & JohnsonXarelto$276$29,69434 claims
AstraZenecaFarxiga$230$20,47925 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →